Free Trial

Kezar Life Sciences (KZR) Competitors

Kezar Life Sciences logo
$4.31 -0.16 (-3.58%)
Closing price 04:00 PM Eastern
Extended Trading
$4.31 0.00 (0.00%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KZR vs. GNLX, MCRB, PLX, SKYE, ONCY, FTLF, TARA, HURA, BHST, and ACTU

Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Genelux (GNLX), Seres Therapeutics (MCRB), Protalix BioTherapeutics (PLX), Skye Bioscience (SKYE), Oncolytics Biotech (ONCY), FitLife Brands (FTLF), Protara Therapeutics (TARA), TuHURA Biosciences (HURA), BioHarvest Sciences (BHST), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

Kezar Life Sciences vs. Its Competitors

Genelux (NASDAQ:GNLX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Kezar Life Sciences' return on equity of -61.15% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -93.04% -74.17%
Kezar Life Sciences N/A -61.15%-50.27%

37.3% of Genelux shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genelux has higher earnings, but lower revenue than Kezar Life Sciences. Genelux is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K12,611.84-$29.87M-$0.88-3.80
Kezar Life Sciences$7M4.50-$83.74M-$10.82-0.40

Genelux has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Genelux presently has a consensus target price of $17.75, suggesting a potential upside of 431.44%. Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 816.47%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Genelux.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Kezar Life Sciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Genelux and Genelux both had 2 articles in the media. Genelux's average media sentiment score of 0.94 beat Kezar Life Sciences' score of 0.93 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kezar Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Kezar Life Sciences beats Genelux on 8 of the 15 factors compared between the two stocks.

Get Kezar Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KZR vs. The Competition

MetricKezar Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$32.66M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.4021.0428.0720.05
Price / Sales4.50284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book0.278.378.665.87
Net Income-$83.74M-$55.19M$3.25B$258.55M
7 Day Performance-0.92%5.89%4.20%2.23%
1 Month Performance5.38%17.63%10.82%12.76%
1 Year Performance-34.53%5.09%34.70%19.36%

Kezar Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KZR
Kezar Life Sciences
4.1969 of 5 stars
$4.31
-3.6%
$39.50
+816.5%
-32.4%$32.66M$7M-0.4060
GNLX
Genelux
1.2316 of 5 stars
$3.51
+5.4%
$17.75
+405.7%
+59.9%$125.74M$10K-3.9910Positive News
Analyst Forecast
Gap Up
MCRB
Seres Therapeutics
3.5046 of 5 stars
$13.85
-1.6%
$73.67
+431.9%
-48.1%$122.86M$126.32M-3.01330Positive News
PLX
Protalix BioTherapeutics
2.9429 of 5 stars
$1.52
+4.8%
$15.00
+886.8%
+34.2%$121.00M$59.76M-11.69200Gap Up
SKYE
Skye Bioscience
2.5339 of 5 stars
$3.73
-4.1%
$16.60
+345.0%
-32.7%$120.49MN/A-4.5511News Coverage
Gap Up
ONCY
Oncolytics Biotech
1.6669 of 5 stars
$1.21
-4.7%
$4.33
+258.1%
+10.7%$119.74MN/A-4.1730News Coverage
Upcoming Earnings
FTLF
FitLife Brands
4.0845 of 5 stars
$12.97
+1.8%
$20.50
+58.1%
-20.0%$119.64M$64.47M15.4420News Coverage
Positive News
Gap Down
TARA
Protara Therapeutics
2.1431 of 5 stars
$3.42
+11.0%
$20.50
+499.4%
+44.0%$118.83MN/A-1.9930
HURA
TuHURA Biosciences
1.7927 of 5 stars
$2.55
-2.7%
$12.67
+396.7%
N/A$114.44MN/A0.00N/A
BHST
BioHarvest Sciences
N/A$6.84
-1.2%
$13.67
+99.8%
N/A$113.66M$25.19M-13.68N/ANews Coverage
ACTU
Actuate Therapeutics
2.3621 of 5 stars
$5.66
-1.7%
$20.50
+262.2%
N/A$113.01MN/A0.0010News Coverage

Related Companies and Tools


This page (NASDAQ:KZR) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners